We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+42.22%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$438M
AUM Growth
+$53.9M
(+14%)
Cap. Flow
+$17.1M
Cap. Flow
% of AUM
3.9%
Top 10 Holdings %
Top 10 Hldgs %
64.1%
Holding
37
New
6
Increased
12
Reduced
11
Closed
8
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
+$17M |
| 2 |
Phreesia
PHR
|
+$12.7M |
| 3 |
HOLX
Hologic
HOLX
|
+$9.71M |
| 4 |
Viatris
VTRS
|
+$8.37M |
| 5 |
Quest Diagnostics
DGX
|
+$7.3M |
Top Sells
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$11.2M |
| 2 |
CMD
Cantel Medical Corporation
CMD
|
+$10.1M |
| 3 |
HMSY
HMS Holdings Corp.
HMSY
|
+$7.75M |
| 4 |
Pacira BioSciences
PCRX
|
+$6.48M |
| 5 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$6.05M |
Sector Composition
| 1 | Healthcare | 92.28% |
| 2 | Industrials | 4.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Medtronic
MDT
$107B
| $43.8M | 10.02% |
385,000
-15,000
| -4% | -$1.65M |
|
2
Bio-Rad Laboratories Class A
BIO
$8.05B
| $36.7M | 8.38% |
100,000
-15,000
| -13% | -$5.29M |
|
|
MDRX
3
DELISTED
Veradigm Inc. Common Stock
MDRX
| $35.1M | 8.03% |
3,650,000
-575,000
| -14% | -$6.05M |
|
4
AtriCure
ATRC
$1.8B
| $27.9M | 6.38% |
860,000
+10,000
| +1% | +$285K |
|
|
5
Pacira BioSciences
PCRX
$1.01B
| $27.8M | 6.35% |
622,500
-152,500
| -20% | -$6.48M |
|
|
6
Quest Diagnostics
DGX
$23.2B
| $25.7M | 5.88% |
245,000
+70,000
| +40% | +$7.3M |
|
|
HOLX
7
DELISTED
Hologic
HOLX
| $24.6M | 5.63% |
475,000
+195,000
| +70% | +$9.71M |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $21.6M | 4.93% |
2,650,000
-350,000
| -12% | -$1.25M |
|
9
Zimmer Biomet
ZBH
$18.1B
| $18.6M | 4.25% |
128,750
-36,050
| -22% | -$4.98M |
|
|
SRCL
10
DELISTED
Stericycle Inc
SRCL
| $18.6M | 4.25% |
300,000
-50,000
| -14% | -$2.96M |
|
|
11
Johnson & Johnson
JNJ
$602B
| $18M | 4.12% |
+125,000
| New | +$17M |
|
|
12
Phreesia
PHR
$673M
| $17.5M | 4.01% |
660,000
+460,000
| +230% | +$12.7M |
|
|
PTLA
13
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $14.3M | 3.26% |
595,000
-405,000
| -41% | -$11.2M |
|
14
Integer Holdings
ITGR
$3.38B
| $13.4M | 3.05% |
165,000
+50,000
| +43% | +$3.82M |
|
15
United Therapeutics
UTHR
$22.5B
| $13.1M | 2.99% |
151,400
+76,400
| +102% | +$6.72M |
|
16
ICU Medical
ICUI
$4.05B
| $13M | 2.97% |
70,000
+35,000
| +100% | +$6.02M |
|
17
Lantheus
LNTH
$6.84B
| $12.5M | 2.85% |
650,000
-100,000
| -13% | -$2.02M |
|
18
Rigel Pharmaceuticals
RIGL
$771M
| $11.8M | 2.69% |
575,000
+27,500
| +5% | +$566K |
|
|
19
Viatris
VTRS
$20.2B
| $9.09M | 2.08% |
+450,000
| New | +$8.37M |
|
|
OPTN
20
DELISTED
OptiNose
OPTN
| $8.57M | 1.96% |
70,000
+25,000
| +56% | +$3.24M |
|
21
RadNet
RDNT
$4.95B
| $8.27M | 1.89% |
400,000
+75,000
| +23% | +$1.29M |
|
|
STRM
22
DELISTED
Streamline Health Solutions
STRM
| $5.99M | 1.37% |
287,059
+147,059
| +105% | +$2.71M |
|
23
Inogen
INGN
$180M
| $4.98M | 1.14% |
+75,000
| New | +$4.7M |
|
|
NVRO
24
DELISTED
NEVRO CORP.
NVRO
| $4.72M | 1.08% |
40,000
-12,864
| -24% | -$1.27M |
|
|
CORV
25
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $1.02M | 0.23% |
2,500,000
-2,000,000
| -44% | -$3.32M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU